Journal article · 2022 · Open access

Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial

Paul Trafford Heath, Eva P. Galiza, David Neil Baxter, Marta Boffito, Duncan Browne, Fiona M. Burns, David Chadwick, Rebecca Clark, Catherine A. Cosgrove, James Benjamin Galloway, Anna L. Goodman, Amardeep Heer and 33 more

Clinical Infectious Diseases, 76(3), 398–407 · Published 10 October 2022 · DOI 10.1093/cid/ciac803

Open PDFView at the publisherCite this paper

In brief

“Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial” is a 2022 journal article by Paul Trafford Heath and 44 co-authors, published in Clinical Infectious Diseases. OpenAlex counts 73 citations as of 20 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Clinical Infectious Diseases.

Citations
73
Most cited in
2024 (21)
Field-weighted impact
7.56
References
22
Authors
45

Abstract

BACKGROUND: The recombinant protein-based vaccine, NVX-CoV2373, demonstrated 89.7% efficacy against coronavirus disease 2019 (COVID-19) in a phase 3, randomized, observer-blinded, placebo-controlled trial in the United Kingdom. The protocol was amended to include a blinded crossover. Data to the end of the placebo-controlled phase are reported. METHODS: Adults aged 18-84 years received 2 doses of NVX-CoV2373 or placebo (1:1) and were monitored for virologically confirmed mild, moderate, or severe COVID-19 (onset from 7 days after second vaccination). Participants who developed immunoglobulin G (IgG) against nucleocapsid protein but did not show symptomatic COVID-19 were considered asymptomatic. Secondary outcomes included anti-spike (S) IgG responses, wild-type virus neutralization, and T-cell responses. RESULTS: Of 15 185 participants, 13 989 remained in the per-protocol efficacy population (6989 NVX-CoV2373, 7000 placebo). At a maximum of 7.5 months (median, 4.5) postvaccination, there were 24 cases of COVID-19 among NVX-CoV2373 recipients and 134 cases among placebo recipients, a vaccine efficacy of 82.7% (95% confidence interval [CI], 73.3%-88.8%). Vaccine efficacy was 100% (95% CI, 17.9%-100.0%) against severe disease and 76.3% (95% CI, 57.4%-86.8%) against asymptomatic disease. High anti-S and neutralization responses to vaccination were evident, together with S-protein-specific induction of interferon-γ secretion in peripheral blood T cells. Incidence of serious adverse events and adverse events of special interest were similar between groups. CONCLUSIONS: A 2-dose regimen of NVX-CoV2373 conferred a high level of ongoing protection against asymptomatic, symptomatic, and severe COVID-19 through >6 months postvaccination. A gradual decrease of protection suggests that a booster may be indicated. CLINICAL TRIALS REGISTRATION: EudraCT, 2020-004123-16.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Heath, P. T., Galiza, E. P., Baxter, D. N., Boffito, M., Browne, D., Burns, F. M., Chadwick, D., Clark, R., Cosgrove, C. A., Galloway, J. B., Goodman, A. L., Heer, A., Higham, A. D., Iyengar, S., Jeanes, C., Kalra, P. A., Kyriakidou, C., Bradley, J. M., Munthali, C., . . . Toback, S. L. (2022). Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial. Clinical Infectious Diseases, 76(3), 398–407. https://doi.org/10.1093/cid/ciac803

MLA 9

Heath, Paul Trafford, et al. “Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial.” Clinical Infectious Diseases, vol. 76, no. 3, 2022, pp. 398–407. https://doi.org/10.1093/cid/ciac803.

Chicago

Heath, Paul Trafford, Eva P. Galiza, David Neil Baxter, Marta Boffito, Duncan Browne, Fiona M. Burns, David Chadwick, et al. 2022. “Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial.” Clinical Infectious Diseases 76 (3): 398–407. https://doi.org/10.1093/cid/ciac803.

Harvard

Heath, P. T. et al. (2022) ‘Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial’, Clinical Infectious Diseases, 76(3), pp. 398–407. doi:10.1093/cid/ciac803.

IEEE

P. T. Heath et al., “Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial,” Clinical Infectious Diseases, vol. 76, no. 3, pp. 398–407, 2022, doi: 10.1093/cid/ciac803.

BibTeX

@article{heath2022safety,
  title     = {{Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial}},
  author    = {Heath, Paul Trafford and Galiza, Eva P. and Baxter, David Neil and Boffito, Marta and Browne, Duncan and Burns, Fiona M. and Chadwick, David and Clark, Rebecca and Cosgrove, Catherine A. and Galloway, James Benjamin and Goodman, Anna L. and Heer, Amardeep and Higham, Andrew D. and Iyengar, Shalini and Jeanes, Christopher and Kalra, Philip A. and Kyriakidou, Christina and Bradley, Judy Martina and Munthali, Chigomezgo and Minassian, Angela M. and McGill, Fiona and MOORE, PATRICK J. and Munsoor, Imrozia and Nicholls, Helen and Osanlou, Orod and Packham, Jonathan and Pretswell, Carol and Ramos, Alberto San Francisco and Saralaya, Dinesh and Sheridan, Ray and others},
  journal   = {Clinical Infectious Diseases},
  year      = {2022},
  volume    = {76},
  number    = {3},
  pages     = {398--407},
  doi       = {10.1093/cid/ciac803},
  url       = {https://doi.org/10.1093/cid/ciac803}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202222
20232020
20242121
20252121
202699

Its field-weighted citation impact is 7.56: it has been cited 7.56 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research

  • NVX-CoV2373
  • COVID-19 vaccines
  • recombinant protein vaccine
  • vaccine efficacy
  • SARS-CoV-2
  • anti-spike IgG
  • virus neutralization
  • T cell response

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Heath, P. T., Galiza, E. P., Baxter, D. N., Boffito, M., Browne, D., Burns, F. M., Chadwick, D., Clark, R., Cosgrove, C. A., Galloway, J. B., Goodman, A. L., Heer, A., Higham, A. D., Iyengar, S., Jeanes, C., Kalra, P. A., Kyriakidou, C., Bradley, J. M., Munthali, C., . . . Toback, S. L. (2022). Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial. Clinical Infectious Diseases, 76(3), 398–407. https://doi.org/10.1093/cid/ciac803

How many times has this paper been cited?

73 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Clinical Infectious Diseases: sign in and open the PDF from this page.

Who wrote this paper?

Paul Trafford Heath, Eva P. Galiza, David Neil Baxter, Marta Boffito, Duncan Browne, Fiona M. Burns, David Chadwick, Rebecca Clark, Catherine A. Cosgrove, James Benjamin Galloway, Anna L. Goodman, Amardeep Heer and 33 more.

What is the DOI of this paper?

10.1093/cid/ciac803, permanently at https://doi.org/10.1093/cid/ciac803. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.